Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lower dose of pregabalin reduce pain and opioid use after surgery?

NCT ID NCT07456761

Symptom relief Sponsor: South Egypt Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether a low dose (82.5 mg) or standard dose (165 mg) of pregabalin retard works better for pain after laparoscopic abdominal surgery. About 80 adults will take one dose before surgery, and researchers will track their pain levels and opioid use for 24 hours. The goal is to find the best dose that controls pain with fewer side effects like dizziness or nausea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pregabalin retard
What this could lead to
If successful, this could show that a lower dose of pregabalin works as well as a higher dose for pain control, with fewer side effects.
What could go wrong
This is a small, early-stage trial with only 80 participants, so results may not apply to everyone. The lower dose might not control pain as effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years * ASA physical status I-III * Scheduled for elective laparoscopic abdominal surgery under general anesthesia (e.g. laparoscopic cholecystectomy, appendectomy, diagnostic/therapeutic laparoscopic procedures without expected conversion to open surgery) * Ability to understand the NRS pain scale and the study procedures * Written informed consent obtained Exclusion Criteria: * Known allergy or intolerance to pregabalin, gabapentinoids, or study medications * Chronic opioid use (daily use \>30 mg oral morphine equivalent for \>2 weeks preoperatively) * Regular use of gabapentin or pregabalin within 30 days * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or on dialysis * Severe hepatic impairment (Child-Pugh C) * Uncontrolled epilepsy or other major neurological disorder * Severe psychiatric disease, alcohol or substance abuse * Pregnancy or breastfeeding * Planned postoperative ICU admission for reasons other than routine overnight monitoring * Conversion to open abdominal surgery (these patients will be analyzed in sensitivity or excluded, predefined in analysis plan)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Laparoscopic abdominal surgeries are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Laparoscopic abdominal surgeries

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.